USP Center in Ghana Receives International Lab Accreditation - - BioPharm International

ADVERTISEMENT

USP Center in Ghana Receives International Lab Accreditation


The US Pharmacopeial Convention (USP) has announced that its Center for Pharmaceutical Advancement and Training has received a top international laboratory accreditation. Launched in May 2013 to promote access to good quality medicines, the center is one of the only few laboratories in Sub-Saharan Africa to meet internationals standards in conducting quality control testing of medicines. The center serves all Sub-Saharan Africa—a region facing serious health issues and a proliferation of substandard and counterfeit medicines.

“We serve as a resource to countries throughout Sub-Saharan Africa by equipping regulatory authorities, manufacturers, quality control professionals, and others in the pharmaceutical industry with knowledge and skills to help ensure good quality medicines,” said Patrick Lukulay, PhD, vice-president for the USP department overseeing this effort, in a press release.

“Having an internationally accredited laboratory available as a training facility is a tremendous resource for the entire region,” said Lukulay. “The ISO 17025 accreditation, which came in record time, demonstrates the quality of our programs, the dedication of our staff in Ghana and USP’s commitment to global health.”

The center, located in Accra, Ghana, received the ISO 17025 accreditation from ACLASS, one of the three brands of the ANSI-ASQ National Accreditation Board, an internationally recognized body responsible for granting ISO/IEC accreditations to high quality testing and calibration laboratories. Preparations for obtaining the lab accreditation took place as staff was conducting training programs for regulators and manufacturers in quality control, GMPs, and dossier evaluation.

Source: USP.org

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here